Rigel Pharmaceuticals risk profile
29 Normal where most of the sector sits
Measured 21 October 2026 from RIGL's filed statements. Recomputed nightly.
29 (Normal), driven by Concentration at 65, over 6 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 50 | Elevated | Volatile | One-year price volatility — 63.5% |
| Operating pressure | 0 | Contained | Stable | Costs outgrowing revenue — -55.3 percentage points |
| Cash conversion | 44 | Elevated | Worsening | Cash conversion — 0.21x |
| Leverage and coverage | 9 | Contained | Easing | Current ratio — 2.42x |
| Competitive position | 20 | Normal | Stable | R&D-intensity gap against peers — -15.8 percentage points |
| Concentration | 65 | Stretched | Easing | Customer concentration — 2,321 HHI |
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for Rigel Pharmaceuticals